Outlive
LongevityResearchHub
Preliminary — 30/100 Review / Commentary PubMed

How FSTL1 Protein Controls Inflammation and Aging—A Research Review

Signalling pathways regulated by FSTL1 in inflammation and potential therapeutic applications (Review).

International journal of molecular medicine February 12, 2026 Ma Changliang, Li Jingxin, Jiang Wenting, Chen Xiaoqiang, Liu Jianquan, Tao Xu, Li Wencui, Deng Zhiqin, Zhao Zhe
TL;DR

This review examines follistatin-like protein 1 (FSTL1), a secreted protein that regulates inflammation, cellular aging, and tumor growth through multiple signaling pathways. The authors propose FSTL1 as a promising therapeutic target for age-related diseases like osteoarthritis, though the evidence base remains largely preliminary.

Credibility Assessment Preliminary — 30/100
Study Design
Rigor of the research methodology
4/20
Sample Size
Whether the study was sufficiently powered
2/20
Peer Review
Review status and journal reputation
11/20
Replication
Has this finding been independently reproduced?
4/20
Transparency
Funding disclosure and data availability
9/20
Overall
Sum of all five dimensions
30/100

What this means

FSTL1 is an intriguing protein involved in inflammation and aging, but this is a high-level overview rather than definitive evidence. It signals promising research directions—particularly for osteoarthritis—but human clinical data is still needed before considering it a validated therapeutic target.

Red Flags: Review article with no new experimental data; zero citations (very recent publication); relies on synthesis of prior work without systematic methodology or quality appraisal; most supporting evidence appears to be from cell culture and animal models rather than human studies; lacks registered protocol or transparency statement; no conflict-of-interest disclosure provided in abstract.

Aging is fundamentally driven by chronic inflammation and cellular dysfunction. One emerging player in this process is FSTL1, a secreted protein found throughout the body. This review synthesizes existing research on how FSTL1 influences three hallmarks of aging: inflammation, cellular senescence (when cells stop dividing and become dysfunctional), and tumor progression. Understanding these mechanisms could reveal new drug targets.

The authors describe FSTL1's structure and its known biological roles. It works both locally (autocrine) and on distant cells (paracrine), affecting cell survival, proliferation, differentiation, and immune function. Critically, FSTL1 appears to operate differently depending on context—sometimes promoting inflammation, sometimes suppressing it. It influences three major cellular signaling pathways: TGF-β (involved in tissue fibrosis and immune regulation), NF-κB (a master inflammation regulator), and MAPK (controlling cell division and stress responses).

The strongest evidence presented involves FSTL1 in osteoarthritis. Studies show elevated FSTL1 in inflamed joint tissues from osteoarthritis patients, and experimental work demonstrates it promotes inflammation in nucleus pulposus cells (intervertebral disc components). This provides a concrete link between FSTL1 levels and age-related joint degeneration. However, most evidence comes from cell culture and animal models, not human clinical studies.

A key limitation is that this is a narrative review, not a systematic analysis. The authors surveyed published work without a pre-specified protocol, search strategy, or quality assessment—making it vulnerable to selective citation. With zero citations so far (publication date April 2026), independent replication is absent. The paper also lacks sufficient detail on human data: most cited findings appear preliminary, and the therapeutic potential remains largely theoretical.

For longevity science, FSTL1 represents an understudied protein in aging. Its role in senescence and inflammation aligns with core aging mechanisms. However, translating this knowledge into therapeutics requires rigorous clinical trials and biomarker validation. Currently, this is a 'promising lead' rather than actionable science—useful for generating hypotheses but not yet ready to guide treatment decisions.

Biomarkers of Aging Regulatory Senescence Senolytics
View Original Source

0 Comments